Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

TGXSF / Tigenix Sa SC14D9C

2018-02-16 sec.gov
    SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 14D-9 (RULE 14d-101)   SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934     TiGenix (Name of Subject Company)     TiGenix (Name of Person(s) Filing Statement)     Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each representing 20 Shares (Title of Class of Securities)   ISIN BE0003864817 (Shares) CUSIP 88675R109 (ADSs) (CUSIP Number of C

TGXSF / Tigenix Sa / Cormorant Asset Management, LLC - 3G/A (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G       Under the Securities Exchange Act of 1934       (Amendment No. 2)*     TiGenix NV     (Name of Issuer)     Ordinary Shares, no par value per share     (Title of Class of Securities)     88675R109     (CUSIP Number)     December 31, 2017     (Date of Event which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ]           

TGXSF / Tigenix Sa / Cormorant Asset Management, LLC - 3G/A (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G       Under the Securities Exchange Act of 1934       (Amendment No. 2)*     TiGenix NV     (Name of Issuer)     Ordinary Shares, no par value per share     (Title of Class of Securities)     88675R109     (CUSIP Number)     December 31, 2017     (Date of Event which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ]           

TGXSF / Tigenix Sa 6-K (Current Report of Foreign Issuer)

2018-02-15 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Form 6-K     REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of February 2018   Commission File Number 001-37965     TiGenix     Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

TGXSF / Tigenix Sa SC 14D9

2018-02-15 sec.gov
    SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 14D-9 (RULE 14d-101)   SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934     TiGenix (Name of Subject Company)     TiGenix (Name of Person(s) Filing Statement)     Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each representing 20 Shares (Title of Class of Securities)   ISIN BE0003864817 (Shares) CUSIP 88675R109 (ADSs) (CUSIP Number of C

TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer)

2018-02-15 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or

TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer)

2018-01-31 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Bone Therapeutics: In (Re)Search For Money

2018-01-31 seekingalpha
On October 31, I released a focus article on Bone Therapeutics (OTC:BNZPF). On one hand, I was fairly excited about the crucial phase III interim results on osteonecrosis that are expected in H2 2018. On the other hand, I also warned investors on the less comfortable cash position of the company. In my previous estimates, I presumed a cash runway until May 2018. This article is intended to discuss recent developments concerning the company's cash position.

TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer)

2018-01-29 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or

TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer)

2018-01-22 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or

TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer)

2018-01-22 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or

TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer)

2018-01-17 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or

TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer)

2018-01-16 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or

TGXSF / Tigenix Sa FORM 6-K (Current Report of Foreign Issuer)

2018-01-16 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-37965 TiGenix (Translation of registrant's name into English) Romeinse straat 12 3001 Leuven, Belgium (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or

TGXSF / Tigenix Sa / TAKEDA PHARMACEUTICAL CO LTD - SC 13D (Activist Investment)

2018-01-12 sec.gov
SC 13D     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.     )*     TiGenix (Name of Issuer) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each representing 20 Shares (Title of Class of Securities) ISIN BE0003864817 (Shares) CUSIP 88675R109 (ADSs) (CUSIP Number) James Kehoe Takeda Pharmaceutical Company Limited 12-10, Nihonbashi 2-Chome, Chuo-ku, Tokyo 103-8668


CUSIP: 88675R109